About rockwell medical - RMTI
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini on October 25, 1996 and is headquartered in Wixom, MI.
RMTI At a Glance
Rockwell Medical, Inc.
30142 South Wixom Road
Wixom, Michigan 48393
| Phone | 1-248-960-9009 | Revenue | 69.26M | |
| Industry | Medical Specialties | Net Income | -5,314,000.00 | |
| Sector | Health Technology | Employees | 157 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
RMTI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.433 |
| Price to Book Ratio | 0.888 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.987 |
| Enterprise Value to Sales | 0.252 |
| Total Debt to Enterprise Value | 0.714 |
RMTI Efficiency
| Revenue/Employee | 441,133.758 |
| Income Per Employee | -33,847.134 |
| Receivables Turnover | 8.505 |
| Total Asset Turnover | 1.19 |
RMTI Liquidity
| Current Ratio | 3.984 |
| Quick Ratio | 3.626 |
| Cash Ratio | 2.609 |
RMTI Profitability
| Gross Margin | 16.886 |
| Operating Margin | -6.773 |
| Pretax Margin | -7.673 |
| Net Margin | -7.673 |
| Return on Assets | -9.134 |
| Return on Equity | -15.277 |
| Return on Total Capital | -10.746 |
| Return on Invested Capital | -11.647 |
RMTI Capital Structure
| Total Debt to Total Equity | 33.725 |
| Total Debt to Total Capital | 25.22 |
| Total Debt to Total Assets | 21.825 |
| Long-Term Debt to Equity | 28.62 |
| Long-Term Debt to Total Capital | 21.402 |